¸¸¼º°ñ¼öÁõ½ÄÁúȯ ¿¬±¸È¸ ½ÉÆ÷Áö¿ò °³ÃÖ ¾È³»
´ëÇÑÇ÷¾×ÇÐȸ ¸¸¼º°ñ¼öÁõ½ÄÁúȯ ¿¬±¸È¸ ½ÉÆ÷Áö¿òÀÌ ¾Æ·¡¿Í °°ÀÌ °³ÃÖµÇ´Ï ¸¹Àº °ü½É°ú Âü¼® ºÎŹµå¸³´Ï´Ù.
»çÀüµî·ÏÀº 11¿ù 21ÀÏ(¼ö)±îÁö µî·ÏÇÏ¿© ÁÖ½Ã±æ ºÎŹµå¸®¸ç, ±âŸ ÀÚ¼¼ÇÑ ³»¿ëÀº ÷ºÎÈÀÏÀ» ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
= ¾Æ·¡ =
ÁÖÁ¦ : ¸¸¼º°ñ¼öÁõ½ÄÁúȯÀÇ Áø´Ü°ú Ä¡·áÁöħ
ÀϽà : 2007³â 11¿ù 24ÀÏ(Åä) 12:30~17:30
Àå¼Ò : ÇѸ²´ëÇб³¼º½Éº´¿ø(ÆòÃÌ) Á¦2º°°ü 5Ãþ Àϼ۹®ÈȦ(¾àµµ ÷ºÎÈÀÏ ÂüÁ¶)
¿¬¼öÆòÁ¡ : ´ëÇÑÀÇ»çÇùȸ 3ÆòÁ¡
»çÀüµî·Ï : ´ëÇÑÇ÷¾×ÇÐȸ »ç¹«½Ç(hematology@kams.or.kr)
¸¶°¨ÀÏ : 2007³â 11¿ù 21ÀÏ(¼ö)±îÁö hematology@kams.or.kr
¹®ÀÇó : ¢Ï 02) 516-6581 FAX 02) 516-6582
Âü°¡ºñ ¹× ÁÖÂ÷ºñ : ¹«·á
* ½ÉÆ÷Áö¿ò ½ÃÀÛÀü¿¡ °£´ÜÇÑ Á¡½É ¹× ´Ù°ú(»÷µåÀ§Ä¡, ±è¹ä, Ä¿ÇÇ µî)°¡ ÁغñµÇ¾î ÀÖ½À´Ï´Ù.
ÇÁ·Î±×·¥
1ºÎ : ÁÂÀå Á¶ÇöÂù(ÇѸ²ÀÇ´ë)
13:10 - 13:40 Evolution of disease entities and diagnostic criteria of CMPD: From WHO 2001 to WHAT?
±èÈñÁø(¼º±Õ°üÀÇ´ë)
13:45 - 14:15 JAK2 V617F À¯ÀüÀÚ µ¹¿¬º¯ÀÌ °Ë»ç¹æ¹ýÀÇ ºñ±³
ÁöÇö¼÷(¿ï»êÀÇ´ë)
14:20 - 14:50 ¸¸¼º°ñ¼öÁõ½ÄÁúȯÀÇ ±¹³» ¿ªÇÐ ¹× µî·Ï»ç¾÷ÀÇ ÇöȲ
¹æ¼ö¹Ì(¼¿ïÀÇ´ë)
2ºÎ : ÁÂÀå ±èö¼ö(ÀÎÇÏÀÇ´ë)
15:10 - 15;35 Áø¼ºÀûÇ÷±¸Áõ´ÙÁõÀÇ Ä¡·áÁöħ
¿øÁ¾È£(¼øõÇâÀÇ´ë)
15:40 - 16:05 Áø¼º°íÇ÷¼ÒÆÇÁõÀÇ Ä¡·áÁöħ
±èºÀ¼®(¼¿ïº¸Èƺ´¿ø)
16:10 - 16:40 Risk and management of complications in patients with CMPD
Á¤Ã¶¿ø(¼º±Õ°üÀÇ´ë)
16:45 - 17:15 Treatment of HES in the era of target therapy
±èÈ¿Á¤(ÇѸ²ÀÇ´ë)
»çÀüµî·ÏÀº 11¿ù 21ÀÏ(¼ö)±îÁö µî·ÏÇÏ¿© ÁÖ½Ã±æ ºÎŹµå¸®¸ç, ±âŸ ÀÚ¼¼ÇÑ ³»¿ëÀº ÷ºÎÈÀÏÀ» ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
= ¾Æ·¡ =
ÁÖÁ¦ : ¸¸¼º°ñ¼öÁõ½ÄÁúȯÀÇ Áø´Ü°ú Ä¡·áÁöħ
ÀϽà : 2007³â 11¿ù 24ÀÏ(Åä) 12:30~17:30
Àå¼Ò : ÇѸ²´ëÇб³¼º½Éº´¿ø(ÆòÃÌ) Á¦2º°°ü 5Ãþ Àϼ۹®ÈȦ(¾àµµ ÷ºÎÈÀÏ ÂüÁ¶)
¿¬¼öÆòÁ¡ : ´ëÇÑÀÇ»çÇùȸ 3ÆòÁ¡
»çÀüµî·Ï : ´ëÇÑÇ÷¾×ÇÐȸ »ç¹«½Ç(hematology@kams.or.kr)
¸¶°¨ÀÏ : 2007³â 11¿ù 21ÀÏ(¼ö)±îÁö hematology@kams.or.kr
¹®ÀÇó : ¢Ï 02) 516-6581 FAX 02) 516-6582
Âü°¡ºñ ¹× ÁÖÂ÷ºñ : ¹«·á
* ½ÉÆ÷Áö¿ò ½ÃÀÛÀü¿¡ °£´ÜÇÑ Á¡½É ¹× ´Ù°ú(»÷µåÀ§Ä¡, ±è¹ä, Ä¿ÇÇ µî)°¡ ÁغñµÇ¾î ÀÖ½À´Ï´Ù.
ÇÁ·Î±×·¥
1ºÎ : ÁÂÀå Á¶ÇöÂù(ÇѸ²ÀÇ´ë)
13:10 - 13:40 Evolution of disease entities and diagnostic criteria of CMPD: From WHO 2001 to WHAT?
±èÈñÁø(¼º±Õ°üÀÇ´ë)
13:45 - 14:15 JAK2 V617F À¯ÀüÀÚ µ¹¿¬º¯ÀÌ °Ë»ç¹æ¹ýÀÇ ºñ±³
ÁöÇö¼÷(¿ï»êÀÇ´ë)
14:20 - 14:50 ¸¸¼º°ñ¼öÁõ½ÄÁúȯÀÇ ±¹³» ¿ªÇÐ ¹× µî·Ï»ç¾÷ÀÇ ÇöȲ
¹æ¼ö¹Ì(¼¿ïÀÇ´ë)
2ºÎ : ÁÂÀå ±èö¼ö(ÀÎÇÏÀÇ´ë)
15:10 - 15;35 Áø¼ºÀûÇ÷±¸Áõ´ÙÁõÀÇ Ä¡·áÁöħ
¿øÁ¾È£(¼øõÇâÀÇ´ë)
15:40 - 16:05 Áø¼º°íÇ÷¼ÒÆÇÁõÀÇ Ä¡·áÁöħ
±èºÀ¼®(¼¿ïº¸Èƺ´¿ø)
16:10 - 16:40 Risk and management of complications in patients with CMPD
Á¤Ã¶¿ø(¼º±Õ°üÀÇ´ë)
16:45 - 17:15 Treatment of HES in the era of target therapy
±èÈ¿Á¤(ÇѸ²ÀÇ´ë)